Serum Vascular Adhesion Protein-1 Predicts 10-Year Cardiovascular and Cancer Mortality in Individuals With Type 2 Diabetes

doi:10.2337/db10-0607

Chia Nan University of Pharmacy & Science Institutional Repository > 環境永續暨休閒學院 > 職業安全衛生系(含防災所) > 期刊論文 > Item 310902800/27022

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/27022

標題:	Serum Vascular Adhesion Protein-1 Predicts 10-Year Cardiovascular and Cancer Mortality in Individuals With Type 2 Diabetes
作者:	Li, Hung-Yuan Jiang, Yi-Der Chang, Tien-Jyun Wei, Jung-Nan Lin, Mao-Shin Lin, Cheng-Hsin Chiang, Fu-Tien Shih, Shyang-Rong Hung, Chi Sheng Hua, Cyue-Huei David, J.Smith Vanio, Jani Chuang, Lee-Ming
貢獻者:	職業安全衛生系
關鍵字:	Sensitive Amine Oxidase Hepatocellular-Carcinoma Colorectal-Cancer Leukocyte Binding Tumor Endothelium P-Selectin Disease Risk Overexpression Adipocytes
日期:	2011-03
上傳時間:	2013-10-23 11:55:48 (UTC+8)
出版者:	Amer Diabetes Assoc
摘要:	OBJECTIVE Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients. RESEARCH DESIGN AND METHODS Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan. RESULTS The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17–4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17–28.97) for cardiovascular mortality, 6.32 (95% CI 1.25–32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57–65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly. CONCLUSIONS Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors
關聯:	Diabetes , 60(3), pp.993-999
显示于类别:	[職業安全衛生系(含防災所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	1672	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....